We develop innovative vaccines for coronaviruses and influenza A viruses using recombinant protein and virus-like particle technology as well as live attenuated virus approaches. As there are very few effective antiviral drugs to treat enterovirus and rhinovirus infections (for which it is impossible to develop vaccines given the large number of serotypes), we also aim to identify potent, broad-range and safe inhibitors of enterovirus/rhinovirus replication and to elucidate their mode of action.